If you read Monday’s edition, you’ll know the acronym JCA. We’re going to spend more time with it today, and not just because we enjoy helping you add to your “pharmese” vocabulary, but because of its importance for everyone who wants to sell their products in Europe.
First, the language of origin: A Joint Clinical Assessment (JCA) is the brand-new EU-level review of a drug’s relative clinical effectiveness. It runs in parallel with the EMA’s review of your marketing application, and national health technology assessment (HTA) bodies must give the resulting report “due consideration” when they make their own pricing and reimbursement calls.
Now that the first-ever Joint Clinical Assessment has been published, if you develop drugs for small populations, you should treat it less like a milestone and more like a fire drill held in your building, with the alarm still ringing.
The subject was Ipsen’s Ojemda (tovorafenib), a treatment for a rare pediatric brain tumor. The result was a 150-plus-page clinical assessment that, when you read past the ceremony, seems more like a warning list of the exact problems you are going to have.
JCAs became applicable to new oncology drugs and advanced therapies in January 2025. They reach orphan medicines in January 2028 and everything else in 2030. Ojemda landed in the first wave because it is a rare cancer, which means it arrived as a kind of accidental preview of the orphan era that is still eighteen months away.
Here is what the preview showed, in five parts.
The Math: Not One of Eight, but Zero of Eight That Count
The number you may have seen is that Ipsen answered only one of eight PICO questions. PICO (population, intervention, comparator and outcome) is the framework member states use to define what they want to know about your drug. Eight of these were put to Ipsen across three patient populations, and the company submitted data for two of them. PICO 7 was thrown out because the assessors found insufficient information on the comparator study, which leaves exactly one, PICO 5, standing in the published report.